Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary Objectives:
- To compare levels of patient anxiety, pain, and satisfaction associated with optical spectroscopy procedures and MDC with the levels associated with colposcopically-directed biopsy in the cervical cancer diagnostic setting and with Papanicolaou smear in the screening setting. This aim will be addressed in Studies A and A' -- Procedure-Related Distress and Patient Satisfaction.
- To evaluate differences in psychological distress, satisfaction, and adherence to treatment in the two arms of a randomized trial; one group will be diagnosed with usual care procedures (Papanicolaou smear and colposcopically-directed biopsy) plus optical spectroscopy and the second will receive usual care. Aim 2 will be accomplished in Study B -- Psychological Distress, Satisfaction, and Adherence Outcomes in a Randomized Trial of Optical Spectroscopy.
- To assess the psychosocial and behavioral impact of a false positive screening result. This will be done in Study C -- Impact of False Positive Screening Test on Psychological Distress and Future Screening Intentions.
- To assess provider receptivity to optical spectroscopy. Aim 4 will be accomplished in Study D -- Survey of Health Care Providers.
| Condition | Intervention |
|---|---|
|
Psychosocial Cervical Cancer |
Behavioral: Questionnaire |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Patient Satisfaction and Psychological Distress Related to Emerging Technologies for Cervical Cancer Screening and Diagnosis |
- Compare levels of patient anxiety, pain, and satisfaction associated with optical spectroscopy procedures and MDC with the levels associated with colposcopically-directed biopsy [ Time Frame: 9 Years ] [ Designated as safety issue: No ]
- Evaluate differences in psychological distress, satisfaction, and adherence to treatment. [ Time Frame: 9 Years ] [ Designated as safety issue: No ]
- Assess the psychosocial and behavioral impact of a false positive screening result. [ Time Frame: 9 Years ] [ Designated as safety issue: No ]
- Assess provider receptivity to optical spectroscopy [ Time Frame: 9 Years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 5885 |
| Study Start Date: | July 1999 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
A
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
|
Behavioral: Questionnaire
Questionnaire
|
|
A'
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
|
Behavioral: Questionnaire
Questionnaire
|
|
B
Patients who have consented to participate in a randomized trial of optical spectroscopy.
|
Behavioral: Questionnaire
Questionnaire
|
|
C
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
|
Behavioral: Questionnaire
Questionnaire
|
|
D
Health care providers.
|
Behavioral: Questionnaire
Questionnaire
|
Detailed Description:
Randomized Clinical Trial:
Participants in this study will be interviewed before and after they see the doctor for their first visit. They will be asked about their moods and the tests used to detect cervical cancer. They will also be asked about their symptom, how it is affecting their lives, and their satisfaction with their visit.
Participants will be called approximately 2 weeks, 6 weeks, and 3 months after their appointments to answer questions about their health and quality of life, and the test and treatment they received. In addition, the participants will complete assessments at the 6, 12, 18, and 24 month clinic visits. If participants do not return for these follow-up appointments, the research staff will attempt to contact the participants to do brief interview by phone.
Research staff will also review participant's medical records and gather information on diagnosis, treatment plans and adherence.
This is an investigational study. A total of 360 patients will take part in this multicenter study. About 180 participants at M. D. Anderson will take part in this study.
Studies A and A Prime:
Participants in this study will be interviewed before they see the doctor. They will be asked about their moods and the tests used to detect cervical cancer.
During the medical tests, participants will rate their pain and how tense they are. Someone will watch them to see whether they are upset or in pain. After they see the doctor, participants will be interviewed again about their mood and how much they liked or did not like the test.
Some participants will be interviewed about their opinion of the test at the appointment when they receive their test results. Some participants will complete the Sequelae of LEEP/biopsy and medication use questionnaire. Some participants will be called 7 to 14 days and/or three months after their appointments. Some participants may answer some of the questions on a computer as well as in an interview. They will be asked to answer questions about their moods and about getting tests to detect cervical cancer. A sample of the participants will be selected to have their results visit tape recorded and to answer a few questions about what the doctor told them.
Participants may be contacted to participate in discussion groups about tests for cervical dysplasia. Participation in the discussion groups is voluntary. Research staff will also review participant's medical records and gather information on diagnosis, treatment plans and adherence.
This is an investigational study. A total of 3980 patients will take part in this multicenter study. About 2400 participants at M. D. Anderson will take part in this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy. Total Accrual for Study A: 3510; Study A': 350; pilot tests for Study A': 120; Study B: 360; and Study C: 645. Health care providers will participate in Study D with a total accrual of 900.
Inclusion Criteria:
Studies A, A', and pilot tests
- Eligible to participate in Project 2
- Over 18
- Referred for an abnormal pap or has no history of abnormal pap
- Consented to participate in the patient outcomes project.
Study B
- Consented to participate in Project 3
- Over 18
- Referred for an abnormal pap
- Consented to participate in the patient outcome project.
Study C
- Same as Study B.
Study D
- Members of the American Society for Colposcopy and Cervical Pathology (ASCCP).
Exclusion Criteria:
Studies A, A', and pilot tests through C:
- Pregnancy
- Unable to communicate in English, Spanish, or Chinese
Study D
- None
Contacts and Locations| United States, Texas | |
| UT MD Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
| LBJ Hospital | |
| Houston, Texas, United States, 77030 | |
| Hermann Professional Building Clinic | |
| Houston, Texas, United States, 77030 | |
| Texas Medical Center Clinic | |
| Houston, Texas, United States, 77030 | |
| Canada, British Columbia | |
| Vancouver General Hospital/British Columbia Cancer Agency | |
| Vancouver, British Columbia, Canada, V5Z 1M9 | |
| Principal Investigator: | Karen Basen-Engquist, PhD | M.D. Anderson Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00473798 History of Changes |
| Other Study ID Numbers: | BS98-269 |
| Study First Received: | May 14, 2007 |
| Last Updated: | March 4, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by M.D. Anderson Cancer Center:
|
Patient Satisfaction Quality of Life Psychological Distress |
Cervical Cancer Cervical Cancer Screening Questionnaire |
Additional relevant MeSH terms:
|
Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site |
Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female |
ClinicalTrials.gov processed this record on May 23, 2013